Radiopharmaceutical developer PETNet, an FDG supplier, has made commitments to open new manufacturing centers and supply radiopharmaceuticals to new customers across the U.S. PETNet two weeks ago announced the signing of a two-way licensing agreement
Radiopharmaceutical developer PETNet, an FDG supplier, has made commitments to open new manufacturing centers and supply radiopharmaceuticals to new customers across the U.S.
PETNet two weeks ago announced the signing of a two-way licensing agreement with Merck for radiopharmaceutical supplies.
Under the agreement, PETNet supplies Merck with radioisotopes, and PETNet obtains rights for new diagnostic radiotracer agents that may be developed by Merck.
Also under the terms of the supply contract, PETNet will open a radiopharmaceutical manufacturing and distribution center near Mercks research and development division in West Point, PA.
This site will produce and supply certain radiotracers for Mercks research and development operation.
The facility will also provide radiopharmaceuticals to other PET scanning centers in Philadelphia and surrounding areas.
PET radiotracers have a half-life of less than two hours, so they must be manufactured close to PET scanning centers. PETNet operates 15 sites throughout the U.S. that use cyclotrons to manufacture radiopharmaceuticals.
In an unconnected agreement with U.S. Oncology, PETNet will supply FDG to U.S. Oncologys one PET imaging site in Dallas. U.S. Oncology is a network of 800 oncologists in 60 cancer centers in 26 states.
The organization plans to open 30 more PET sites within the next two years.
Staff at the M.D. Anderson Cancer Center in Houston said PETNet will help them study PETs diagnostic capabilities more closely when PETNet opens a radiopharmaceutical manufacturing and distribution center in that city.
In a separate agreement, CTI, a supplier of PET products and a major shareholder in PETNet, will supply the M.D. Anderson Cancer Center with Ecat Exact PET scanners.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
Study: Abbreviated Breast MRI Offers Equivalent Accuracy to mpMRI for Women with Dense Breasts
May 20th 2025Emerging research suggests that abbreviated breast MRI offers comparable sensitivity and specificity as multiparametric MRI in women with extremely dense breasts with a nearly 50 percent reduction in reading time for radiologists.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
Study: Abbreviated Breast MRI Offers Equivalent Accuracy to mpMRI for Women with Dense Breasts
May 20th 2025Emerging research suggests that abbreviated breast MRI offers comparable sensitivity and specificity as multiparametric MRI in women with extremely dense breasts with a nearly 50 percent reduction in reading time for radiologists.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
2 Commerce Drive
Cranbury, NJ 08512